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Valorisation as a new mode of governance
in medical genomics?
Genomics as a new innovation regime
Two-year project, Centre for Society and Genomics
• Emergence of genomics involves a transformation of knowledge
production in human genetics
• This transformation also has implications for the process of 
knowledge application in genomics, changing the relationship
between the bench and the clinic
• ‘Valorisation’ as a new challenge in genomics
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Identity of actors?
Knowledge and products exchanged?
Co-ordination of activities?
Relations between actors?
World of innovation can be described on different levels:
• Macro or landscape level of (national) innovation system
• Meso or field level of innovation regimes
A changing (health) innovation system
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A new political economy of knowledge production, changing
contract between science and society …
Valorisation as a response to ‘innovation paradox’
A short history of valorisation
Concept of valorisation introduced in Dutch innovation policy
discourse at the end of the 1990s
• Defined as economic valorisation of academic research
• Acquires special significance in the context of European Lisbon
strategy (2000), aiming at a knowledge economy
A national strategy for genomics
Dutch advisory committee Knowledge Infrastructure Genomics
(Wijffels, 2001)
• Integral approach, looking at innovation chain as a whole
• Public private partnerships (PPP) and valorisation as key factors, 
fostering the protection, transfer and commercial exploitation of 
knowledge
• Genomics as foundation for the future of Dutch industry: 
establishment of Netherlands Genome Initiative, fostering public 
private partnerships (NGI, 2002)
NGI Strategic Plan 2002 - 2006
Develop a world class knowledge infrastructure … firmly 
embedded in society and … yielding a continuous influx of new 
commercial applications (Strategic Plan 2002-2006)
• Valorisation plan: licensing intellectual property and supporting
business start-ups
• Translational research: does not entail commercialisation, but
inclusion of medical innovations in (insured) health care
Evaluation of NGI valorisation activities
(Technopolis 2007)
• Successive valorisation plans had tendency to meander:
from top-down approach emphasising industrial partnerships to 
bottom-up approach supporting research organisations
• In terms of valorisation output – patent applications, licenses, 
spin-offs – NGI performs well
• Translational research did not get sufficient attention
• NGI (2008–2012) will place more emphasis on the utilisation of 
knowledge by its core activities … valorisation will get extra 
attention and will be linked to quantitative targets
(Making the most of genomics, 2008)
Partners in the Polder (2009):
a vision for the life sciences in the Netherlands
• Valorisation as “process of value
creation from knowledge by making it
available for economic and/or social
use by translating it into competitive
products, services, processes or new
commercial activities” (Dutch Innovation
Platform)
• Not only dissemination activities, but
also – demand driven, user-inspired –
research programming and interaction
with stakeholders
Valorisation as mode of governance:
value that can be measured
• Quantified valorisation targets for genomics consortia: dissertations, 
patents, start-up companies, industrial collaboration
• Valorisation events and meetings between researchers and 
entrepreneurs: Genomics Momentum, valorisation managers best 
practices exchanges, business development meetings
• Roles for private parties and Technology Transfer Offices (TTOs) 
are described in valorisation plans of consortia
• Valorisation is promoted with additional financial instruments: 
Venture Challenge, NGI Pre-SeedGrant, BioGenerations Ventures, 
and NGI Valorisation Award
“Developments (in Europe and the USA) show that a country has to 
act aggressively, and needs to have the ambition to become and 
remain one of the top bioregions in the world”
(Partners in the Polder 2009)
Medical genomics:
a new innovation regime
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From clinical genetics to medical genomics:
• Large-scale studies of genetic risk factors for common diseases
• Data collections as platforms linking public and private interests
• Valorisation a new challenge?
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Value creation in medical genomics
• How are processes of value creation in medical genomics as a 
new innovation regime shaped by valorisation as a dominant 
mode of governance on the innovation system level of NGI 
policy-making?
• Importance of other modes of value creation in regime of 
medical genomics through translational research, based on
reciprocal interactions between the bench and the bedside?
Martin et al. From bedside to bench: communities of promise, translational research and the 
making of blood stem cells (2008)
Wainwright et al. Stem cells, translational research and the sociology of science (2009)
Stengel et al. Plant sciences and the public good (2009)
Kaye et al. Patents and translational research in genomics (2007)
Our research project: next steps
• In what ways is – economic and social – value being created in 
various and changing processes of knowledge production in the 
field of medical genomics (as a new innovation regime)?
• What is the significance and impact in this context of valorisation
as dominant mode of governance?
• Duchenne muscular dystrophy and Alzheimer’s disease as case 
studies
